Found: 18
Select item for more details and to access through your institution.
Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.
- Published in:
- Journal of the Peripheral Nervous System, 2022, v. 27, n. 2, p. 159, doi. 10.1111/jns.12487
- By:
- Publication type:
- Article
Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review.
- Published in:
- Journal of the Peripheral Nervous System, 2020, v. 25, n. 3, p. 230, doi. 10.1111/jns.12402
- By:
- Publication type:
- Article
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study.
- Published in:
- Journal of the Peripheral Nervous System, 2019, v. 24, n. 1, p. 72, doi. 10.1111/jns.12303
- By:
- Publication type:
- Article
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
- Published in:
- Journal of the Peripheral Nervous System, 2019, v. 24, n. 1, p. 48, doi. 10.1111/jns.12302
- By:
- Publication type:
- Article
Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial.
- Published in:
- Journal of the Peripheral Nervous System, 2017, v. 22, n. 2, p. 149, doi. 10.1111/jns.12204
- By:
- Publication type:
- Article
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
- Published in:
- Journal of Clinical Immunology, 2018, v. 38, n. 8, p. 864, doi. 10.1007/s10875-018-0560-5
- By:
- Publication type:
- Article
Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency.
- Published in:
- Journal of Clinical Immunology, 2016, v. 36, n. 3, p. 210, doi. 10.1007/s10875-016-0243-z
- By:
- Publication type:
- Article
Erratum to: Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases.
- Published in:
- 2014
- By:
- Publication type:
- Erratum
Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases.
- Published in:
- Journal of Clinical Immunology, 2014, v. 34, n. 2, p. 204, doi. 10.1007/s10875-013-9985-z
- By:
- Publication type:
- Article
Safety and tolerability of IgPro10 in Japanese primary immunodeficiency patients: a registrational study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 8, p. 839, doi. 10.1002/psp4.12647
- By:
- Publication type:
- Article
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks.
- Published in:
- Allergy, Asthma & Clinical Immunology, 2019, v. 15, n. 1, p. N.PAG, doi. 10.1186/s13223-019-0328-3
- By:
- Publication type:
- Article
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
- Published in:
- Orphanet Journal of Rare Diseases, 2021, v. 16, n. 1, p. 1, doi. 10.1186/s13023-020-01658-4
- By:
- Publication type:
- Article
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
- Published in:
- Orphanet Journal of Rare Diseases, 2021, v. 16, n. 1, p. 1, doi. 10.1186/s13023-020-01658-4
- By:
- Publication type:
- Article
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
- Published in:
- 2021
- By:
- Publication type:
- corrected article